相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expressions of ER, PR, HER-2, COX-2, and VEGF in Primary and Relapsed/Metastatic Breast Cancers
Li Sun et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2014)
The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis
Lei Yu et al.
GYNECOLOGIC ONCOLOGY (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MICROVESSEL DENSITY AND EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN CLINICALLY LOCALIZED PROSTATE CANCER
Elzbieta Luczynska et al.
POLISH JOURNAL OF PATHOLOGY (2013)
The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology
Kim R. Kampen
ANTI-CANCER DRUGS (2012)
Prognostic Value of Vascular Endothelial Growth Factor Expression in Resected Gastric Cancer
Lei Liu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Samar Masoumi Moghaddam et al.
CANCER AND METASTASIS REVIEWS (2012)
Antiangiogenic Therapy for Glioblastoma
Elizabeth R. Gerstner et al.
CANCER JOURNAL (2012)
Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
Basel Sitohy et al.
CANCER RESEARCH (2012)
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)
C. P. Belani et al.
CANCER TREATMENT REVIEWS (2012)
A preclinical and clinical review of aflibercept for the management of cancer
Andrew Gaya et al.
CANCER TREATMENT REVIEWS (2012)
Safety Profile and Tolerability of Antiangiogenic Agents in Non-Small-Cell Lung Cancer
Shirish M. Gadgeel
CLINICAL LUNG CANCER (2012)
Targeted therapeutic strategies for the management of renal cell carcinoma
Eric A. Singer et al.
CURRENT OPINION IN ONCOLOGY (2012)
Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer
A. D. Karatzanis et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2012)
Approach to the patient with advanced differentiated thyroid cancer
M. Schlumberger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Sorafenib in melanoma
Joanna Mangana et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Current status of targeted therapies in advanced gastric cancer
Ferdinando De Vita et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)
George R. Blumenschein
INVESTIGATIONAL NEW DRUGS (2012)
Therapeutic strategies in epithelial ovarian cancer
Ayako Kim et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Tumor Vasculature as a Therapeutic Target in Non-small Cell Lung Cancer
Jair Bar et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
Melchiorre Cervello et al.
ONCOTARGET (2012)
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
Bingxue Shang et al.
Frontiers of Medicine (2012)
Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer
R. A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic Significance of Angiogenesis and Angiogenic Growth Factors in Nonsmall Cell Lung Cancer
Ravi Salgia
CANCER (2011)
Targeted Therapies for Lung Cancer Clinical Experience and Novel Agents
Jill E. Larsen et al.
CANCER JOURNAL (2011)
Basic and Therapeutic Aspects of Angiogenesis
Michael Potente et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis
Elena Galfrascoli et al.
DIGESTIVE AND LIVER DISEASE (2011)
New Insights into the Biology of Renal Cell Carcinoma
Lianjie Li et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Shahzad Raza et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2011)
Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Ramon Andrade de Mello et al.
Recent Patents on Anti-Cancer Drug Discovery (2011)
Concise Review: Vascular Stem Cells and Tumor Angiogenesis
Juan M. Melero-Martin et al.
STEM CELLS (2011)
Angiogenesis: A Target in Solid Tumors, Also in Leukemia?
Thomas Schmidt et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Angiogenesis, Lymphangiogenesis, Growth Pattern, and Tumor Emboli in Inflammatory Breast Cancer
Peter B. Vermeulen et al.
CANCER (2010)
microRNAs and lung cancer: tumors and 22-mers
Liqin Du et al.
CANCER AND METASTASIS REVIEWS (2010)
Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development
Beate M. Lichtenberger et al.
CELL (2010)
Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications
Stephen M. Keefe et al.
CLINICAL CANCER RESEARCH (2010)
Current data on predictive markers for anti-angiogenic therapy in thoracic tumours
N. Reinmuth et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
Grzegorz Korpanty et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2010)
Quantifying the Proteolytic Release of Extracellular Matrix-Sequestered VEGF with a Computational Model
Prakash Vempati et al.
PLOS ONE (2010)
Novel Targeted Agents for the Treatment of Bladder Cancer: Translating Laboratory Advances into Clinical Application
Xiaoping Yang et al.
INTERNATIONAL BRAZ J UROL (2010)
Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors
Susan A. J. Vaziri et al.
CURRENT ONCOLOGY REPORTS (2010)
Vascular Endothelial Growth Factor-Related Pathways in Hemato-LymphoidMalignancies
Michael Medinger et al.
JOURNAL OF ONCOLOGY (2010)
Targeting the tumour vasculature: insights from physiological angiogenesis
Alicia S. Chung et al.
NATURE REVIEWS CANCER (2010)
Stroma-epithelium crosstalk in prostate cancer
Yi-Nong Niu et al.
ASIAN JOURNAL OF ANDROLOGY (2009)
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy
Jerry Y. Hsu et al.
BIODRUGS (2009)
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
S. J. Schoenleber et al.
BRITISH JOURNAL OF CANCER (2009)
Angiogenesis in pre-malignant conditions
Marius Raica et al.
EUROPEAN JOURNAL OF CANCER (2009)
Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors
Woo-Young Kim et al.
FEBS JOURNAL (2009)
Tumor Angiogenesis in Melanoma
Alexander G. Marneros
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer A Systematic Review with Meta-Analysis
Ping Zhan et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
Lokesh Jain et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis
Barbara Bonnesen et al.
LUNG CANCER (2009)
MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo
Bo Liu et al.
LUNG CANCER (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC
Nathan A. Pennell et al.
ONCOLOGIST (2009)
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
Masabumi Shibuya
BMB REPORTS (2008)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Inflammation in lung carcinogenesis: New targets for lung cancer chemoprevention and treatment
Jay M. Lee et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance
Shinichi Sakamoto et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
C. Kut et al.
BRITISH JOURNAL OF CANCER (2007)
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts
Anthony Polverino et al.
CANCER RESEARCH (2006)
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
G. Des Guetz et al.
BRITISH JOURNAL OF CANCER (2006)
Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
RM Bremnes et al.
LUNG CANCER (2006)
Vascular endothelial growth factor in the lung
NF Voelkel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells
M Grunewald et al.
CELL (2006)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
Angiogenesis and lung cancer: Prognostic and therapeutic implications
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Vascular endothelial growth factor: Basic science and clinical progress
N Ferrara
ENDOCRINE REVIEWS (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
L Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma
E Kaio et al.
ONCOLOGY (2003)
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena
RV Iozzo et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas
H Mineta et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
